Evidence map›Paper›PMID 38751475›Full record

ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2023

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial.

Qingyuan Zhang, Wei Li, Xichun Hu, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong and 3 more

Abstract read
In one paragraph

Article in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qingyuan ZhangDepartment of Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Wei LiDepartment of Oncology, The First Hospital of Jilin University, Changchun, China.
Xichun HuDepartment of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
Tao SunDepartment of Oncology, Liaoning Cancer Hospital & Institute, Shenyang, China.
Shude CuiDepartment of Breast Cancer Center, Henan Cancer Hospital, Zhengzhou, China.
Shusen WangDepartment of Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Quchang OuyangDepartment of Oncology, Hunan Cancer Hospital, Changsha, China.
Yongmei YinDepartment of Oncology, Jiangsu Province Hospital, Nanjing, China.
Cuizhi GengBreast Cancer Center, Tumour Hospital of Hebei Province, Shijiazhuang, China.
Zhongsheng TongDepartment of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Ying ChengDepartment of Oncology, Jilin Cancer Hospital, Changchun, China.
Zhiqiang NingChipscreen Biosciences Ltd., Shenzhen, China.
Zefei JiangSenior Department of Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The ACE study previously demonstrated that tucidinostat (chidamide), a subtype-selective histone deacetylase (HDAC) inhibitor, plus exemestane significantly improved progression-free survival (PFS) in advanced hormone receptor-positive (HR Methods: ACE is a randomized, double-blind, placebo-controlled, phase 3 trial comparing tucidinostat 30 mg/twice weekly plus exemestane 25 mg/day versus placebo plus exemestane 25 mg/day in postmenopausal patients with advanced, HR Results: Of the 365 patients enrolled between July 2015, and June 2017, 244 were assigned to tucidinostat plus exemestane (tucidinostat group) and 121 to placebo plus exemestane group (placebo group). Baseline characteristics were well balanced between groups. The median follow-up from randomization to data cut-off (February 25, 2021) of this analysis was 26.5 months (range, 13.9-45.5 months). A total of 231 deaths (63.3%) from 365 patients occurred, including 155 deaths (63.5%) in the tucidinostat group and 76 deaths (62.8%) in the placebo group. The median OS was 30.3 months (95% CI, 26.7-36.7) in the tucidinostat group and 30.3 months (95% CI, 24.8-38.1) in the placebo group. The safety profiles of both tucidinostat and placebo groups remained consistent with those previously reported, and no new safety signals were observed with longer follow-up. Neutropenia of grade 3 or 4 occurred in 51.6% of the patients in the tucidinostat group and 2.5% of the patients in the placebo group. Adverse events (AEs) that led to treatment discontinuations from any cause occurred in 28 (11.5%) patients in the tucidinostat group and 4 (3.3%) in the placebo group. Conclusions: Although tucidinostat in combination with exemestane had produced a clinically meaningful and statistically significant improvement in the primary endpoint PFS, the ACE study did not show a prolongation of the secondary endpoint OS in the tucidinostat combination regimen. Ongoing studies have been considered in terms of potential identification of what patient subpopulations could benefit most from the tucidinostat combination regimens in advanced HR

Indexed as

breast cancerChidamide/tucidinostathistone deacetylase inhibitor (HDAC inhibitor)overall survival (OS)safety

Identifiers

PMID38751475
PMCPMC11093016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.